Recurrent Respiratory Papillomatosis

Venkatesan, Naren N.; Pine, Harold S.; Underbrink, Michael P.

doi:10.1016/j.otc.2012.03.006

Cited by 122 publications

(125 citation statements)

References 131 publications

(134 reference statements)

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…As deficient immunity was suspected to be implicated in the clinical course of RRP, various types of vaccinations have been used with curative intention in the patients with RRP [24]. According to the literature data, the following vaccines were administered systemically or intralesionally: autogenous vaccine [25], inactivated tissue culture virus vaccine [26], mumps vaccine [27], HPV 6b L1 virus-like particles [28], and a recombinant fusion protein of Hsp65 from Mycobacterium bovis BCG and E7 protein from HPV 16 [29].…”

Section: Introductionmentioning

confidence: 99%

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Boltežar

Matičič

Šereg-Bahar

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

In the case of an aggressive course of recurrent respiratory papillomatosis (RRP), adjuvant therapy can be used besides surgery. The aim of the study was to investigate the influence of vaccination with a quadrivalent vaccine against human papilloma viruses (HPV) types 6, 11, 16 and 18 on the course of RRP. Eleven subjects aged 13-46 years with a rapid growth of laryngeal papillomas were included in the study. They were vaccinated with three doses of the quadrivalent prophylactic HPV vaccine (Silgard(®), MSD) and followed up for 12-52 months. The intervals between the successive surgical procedures, the extension of the disease (Derkay score) at each surgery, and the number of surgical procedures per year before vaccination and after its completion were compared. The mean interval between the surgical procedures was 271.2 days before the vaccination and 537.4 days after it (p = 0.034). The mean number of surgeries per year was 2.16 before the vaccination and 0.93 after it (p = 0.022). The Derkay score did not change significantly after vaccination. Complete remission of the disease was observed in one patient, partial response to the vaccination was observed in seven patients and no response was observed in three patients. In conclusion, vaccination with the quadrivalent HPV vaccine can favorably influence the course of RRP in patients with the rapid growth of the papillomas. It significantly prolongs the intervals between the surgical procedures and reduces the number of procedures needed in the majority of patients. The present investigation can serve as a pilot study for further research. For a final conclusion a longer follow-up and studies on more patients are necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Boltežar

Matičič

Šereg-Bahar

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…Juvenile-onset Recurrent Respiratory Papillomatosis (JORRP), characterized by recurrent growth of papillomas in the respiratory tract, is the most common benign neoplasm of the larynx in children1. Although relatively rare with 1.4 RRP patients per 100,000 in the general UK population and children of about 4.3 per 100,000 in the USA23, JORRP could cause heavy economic burden on a family by multiple surgery procedures to prevent airway obstruction4.…”

mentioning

confidence: 99%

Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression

Wang

Chen

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Whether humoral immunity plays a role in HPV type 6 or 11 virus-mediated Juvenile-onset Recurrent Respiratory Papillomatosis (JORRP) remains unknown. In the present study, serum total IgG level in 44 JORRP patients was significantly decreased compared with that in 40 healthy controls. Moreover, expanded CD3−CD19+ B cells with down-regulation of CD23, CD40, HLA-DR and up-regulation of CD86 expression were found in the peripheral blood of JORRP patients. Flow cytometry analysis of B-cell compartment showed that the frequency of both CD19+CD27hi plasma cells and CD19+CD27+ memory B cells were decreased in JORRP patients. Importantly, although the proportion of circulating CXCR5+PD1hi Tfh cells was not changed, the function of Tfh cells were greatly impaired with reduced ability of IL-21 secretion to promote B cell maturation. Association analysis by the Kaplan-Meier method revealed that IL-21 secreting Tfh cell was positively correlated to the CD27+ B cell subset frequency, the serum IgG level and the frequency of recurrence in JORRP patients, but negatively correlated to the percentage of IgD+CD27− B cell. We concluded that a reduced IL-21 secretion by Tfh cells may limit B cell maturation and antibody production in JORRP patients and Tfh cell-derived IL-21 might be associated with JORRP outcome in clinic.

show abstract

“…Датские исследовате-ли доказали, что при исследовании в 95% единичных папиллом гортани была обнаружена позитивная ДНК HPV и его гибриды [6,8,27,28]. Исследователи из Гонконга обнаружили в 59% папиллом гортани вирусы HPV6; HPV11; HPV16; HPV18 с преимуществом HPV6-и HPV11-серотипов вируса [11,30].…”

Section: этиологияunclassified

“…Частое развитие рецидивов вынуждает к выполнению неоднократных хирургических вмешательств, в связи с чем в большин-стве случаев у пациентов развиваются рубцовые дефор-мации гортани, иногда приводящие к сужению ее про-света и ухудшению голосовой функции. В среднем в детском и подростковом периодах жизни пациенты с ЮРП переносят около 20 хирургических вмешательств, а у 19% детей число операций превышает 40 [28]. У детей возможно развитие пневмонии.…”

Section: клиническое течениеunclassified